UCB gets FDA Breakthrough Therapy designation for certolizumab pegol in high-risk APS pregnancy
FDA grants UCB Breakthrough Therapy status for certolizumab pegol in high-risk APS pregnancy, based on promising but non-randomized Phase 2 evidence.
Pharma & Biotech